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Uptake and intracellular activity of ketolide HMR 3647 in human phagocytic
and non-phagocytic cells
A. Pascual, S. Ballesta, 1. Garda and E. J. Perea
Department of Microbiology, School of Medicine, Sevilla, Spain
Objective To evaluate the uptake of HMR 3647 into human neutrophils (PMNs), human peritoneal
macrophages (PMOs) and tissue-cultured cells (epithelial cells and fibroblasts), and to assess the intracellular
activity of this drug.
Method Cell uptake of HMR 3647 was measured by radiometric assay, as described by Klemper and Styrt.
Intracellular activity was determined by incubation for 3 h of PMNs containing bacteria in the presence of
HMR 3647.
Results The intracellular concentrations were 130 and 71 times higher than extracellular concentrations in
PMNs and PMOs, respectively (extracellular concentrations: 2-25 mg/L). The cellular-to-extracellular
concentration ratios (C/E) for tissue-cultured cells were lower than those obtained in phagocytic cells but still
greater than 5. The uptake of HMR 3647 was rapid and non-saturable in all cells. HMR 3647 was released
slowly from phagocytic cells. HMR 3647 (extracellular concentration: 0.5-10 mg/L) did not significantly
reduce the intracellular survival rate of Staphylococcus aureus ATCC 25923 in PMNs.
Conclusions HMR 3647 reaches intracellular concentrations several times higher than extracellular
concentrations within phagocytic and non-phagocytic cells. The slow efflux of this drug from phagocytic cells
suggests that these cells may be a vehicle for it, delivering it to sites of infection.
Keywords Intracellular penetration, intracellular activity, ketolide, phagocytes, tissue-cultured, HMR 3647
Accepted 30 November 2000
Clin Microbiol Infect 2001; 7: 65-69
INTRODUCTION
HMR 3647 is a new ketolide derived from erythromycin A,
with a 3-keto group on the erythronolide A ring instead ofan L-
cladinose. This antimicrobial agent displays a similar spectrum
of activity to reference macrolides (erythromycin A) and
improved activity against Gram-positive bacteria [1]. N ever-
theless, HMR 3647 has been demonstrated to be more active
than existing macrolides against erythromycin A-resistant
Gram-positive cocci [2] and to have increased anti-anaerobic
activity [3,4]. This agent is active in vitro against typical
intracellular pathogens such as Chlamydia spp. or Legionella
spp. [5,6]. HMR 3647 has also shown better activity than other
macrolides against Toxoplasma gondii [7,8].
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The penetration and intracellular activity of antimicrobial
agents in phagocytic cells is particularly important in conditions
where the infecting microorganism is able to survive and
multiply within them. Several infecting bacteria, such as Chla-
mydia spp., are able to multiply within non-phagocytic cells,
particularly epithelial cells. For these infections, the use of
agents capable of accumulating and remaining active in such
cells could be of potential clinical interest.
HMR 3647 is strongly accumulated by human polymorpho-
nuclear neutrophils (PMNs), without saturation, and shows
a slow efflux. Uptake depends on environmental temperature,
not extracellular pH, and also impairs oxidant production by
PMNs in a time-dependent manner [9]. Most intracellular
bacteria, however, multiply or survive within macrophages.
There is no information on the intracellular pharmacology of
these compounds in human macrophages (PMOs). Moreover,
substantial intracellular accumulation of an antimicrobial agent
does not always lead to good intracellular activity.
The purpose ofthis study was to evaluate the uptake ofHMR
3647 by phagocytic (PMNs and PMOs) and non-phagocytic
(epithelial cells (McCoy and Hep-2) and fibroblasts (Vero)) cells.
The intracellular activity ofthis compound against Staphylococcus
aureus was also evaluated.
© 2001 Copyrightby the European Society of Clinical Microbiology and Infectious Diseases
66 Clinical Microbiology and Infection, Volume 7 Number 2, February2001
MATERIALS AND METHODS
Isolation ofphagocytes
PMNs were recovered from the heparinized venous blood of
healthy donors and were purified using previously described
methods [10]. PMN preparations were >97% pure. PMOs
were isolated from the peritoneal effluents of patients under-
going continuous ambulatory peritoneal dialysis (CAPD) and
who were being followed up by the Nephrology Department of
the University Hospital of Sevilla, as previously described [11].
Donors were clinically uninfected at the time of the study. Cell
preparations from the CAPD donor always contained>75%
PMOs and <15% PMNs. Final cell suspensions were adjusted
to 5 X 106 PMOs/mL or 5 X 106 PMN/mL in Hanks'
balanced salt solution (HESS) containing 0.1% gelatin
(GHBSS). Both populations of cells were >95% viable by
trypan blue exclusion criteria.
Tissue-cultured cells
McCoy, Hep-2 (tissue-cultured epithelial cells) and Vero cells
(fibroblasts) (Flow Laboratories, Irvine, UK) were grown in a
minimal essential medium (Flow Laboratories) supplemented
with 1 mM HEPES (N-2-hydroxyethylpiperazine-N'-2-
ethanesulfonic acid; Flow Laboratories) and containing 10%
fetal calf serum (Flow Laboratories) without antibiotics. For
each experiment, cells were detached from tissue culture
bottles with trypsin-EDTA (Flow Laboratories), washed
once with minimal essential medium containing fetal calfserum
(10%), and suspended in HBSS at a concentration of 5 X 106
cells/mL.
Ketolide uptake bycells
Uptake of radiolabeled ketolide HMR 3647 by phagocytic and
tissue-cultured cells was determined by means of a velocity
gradient centrifugation technique, as described by Klempner
and Styrt [12]. 14 C _H M R 3647 (2.18 GBq/mmol) and HMR
3647 were kindly supplied by Hoechst Marion Roussel
(Romainville, France). In these experiments, phagocytes or
tissue-cultured cells were incubated in HESS containing dif-
ferent concentrations ofketolide (2, 5, 10 and 25 mg/L). After
different incubation periods at 37°C, cells were separated from
extracellular solution by centrifugation through a water-
impermeable silicone oil barrier in a microcentrifuge tube.
A lO-J-lLaliquot of the extracellular medium and the entire cell
pellet, obtained by cutting offthe portion ofthe microfuge tube
containing the pellet, were placed in 3 mL of scintillation fluid
(Ready Micro, Beckman Instruments, Inc., Fullerton, Ca,
USA) and counted in a liquid scintillation counter (model
LS 1801; Beckman Instruments). After determination of the
cell volume with radiolabeled polyethylene glycol and water
(Amersham International plc. Buckinghamshire, UK), the
accumulation rate of the antimicrobial agent in PMNs, PMOs
or tissue-cultured cells was calculated and expressed as cellular-
to-extracellular concentration ratio (C/E) [11].
The efflux or reversibility of binding of cell-associated
ketolide was also studied. Cells were incubated for 20 min
(PMNs and tissue cells) and 1 h (PMOs) at 37°C with HMR
3647 (extracellular concentration, 2 mg/L), collected by cen-
trifugation, and rapidly suspended in a ketolide-free medium.
Cell-associated ketolide was quantitated at various time inter-
vals after the removal of the extracellular antimicrobial agent.
Organisms and susceptibility testing
Staphylococcus aureus ATCC 25923 was used for killing assays.
Susceptibility studies were determined by dilution assay. The
MIC of HMR 3647 against this strain was 0.06 mg/L.
Intracellular activities ofantimicrobial agents
To evaluate the intracellular activities of antimicrobial agents, a
previously described method was used [11]. Briefly, 0.1 mL of
opsonized bacterial suspension (5 X 107 CFU/mL) and
0.1 mL of PMNs (5 X 106 PMN/mL) were combined in a
series of polypropylene biovials (Beckman) and incubated in a
shaker (250 rev/min) for 60 min at 37°C. After incubation,
extracellular bacteria were removed by differential centrifuga-
tion. Cells were then suspended in 0.2 mL of RPMI medium
(Sigma Chemical Co., St Louis, MO). At this time, different
concentrations of the ketolide were added, and the vials were
incubated in a shaker (50 rev/min) at 37°C. Vials were
removed at time zero and after 3 h of incubation (control
and samples with antimicrobial agents). Cells were lysed in
distilled water, and samples were diluted and pour-plated in
agar. Colonies were counted after 24 h of incubation at 37°C.
The data were expressed as percentages of surviving staphylo-
cocci as compared with control levels (without antimicrobial
agents) at 3 h. In addition to determining bacterial survival,
morphologic studies were also routinely performed at time zero
and after 3 h of incubation to evaluate the disposition of
bacteria (cell associated or extracellular). Samples (50 J-lL) were
removed from biovials and deposited on glass slides. After being
stained with Wright stain, samples were examined by light
microscopy. All assays were performed in duplicate with PMNs
from five different donors.
Statistical analysis ofdata
Data were expressed as mean ± standard deviations. Differ-
ences between groups were compared by analysis of variance,
used to assess statistical significance at P <::: 0.05.
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RESULTS
Accumulation ofHMR 3647
Figure 1 shows the kinetics of the uptake of HMR 3647 by
PMOs and PMNs. HMR 3647 penetrated rapidly into PMOs
and PMNs, providing intracellular concentrations 65 times
higher than the extracellular concentrations after 30 min of
incubation. This C/E ratio remained the same for PMOs after
24 h of incubation, but continued increasing in PMNs, intra-
cellular concentrations 135 times higher than the extracellular
concentrations being reached after 180 min of incubation.
The ketolide uptake into Vero was similar to that obtained
into McCoy (data not shown). The uptake ofHMR 3647 into
the epithelial cells (McCoy, Hep-2) is shown in Figure 2.
Uptake, after 30 min of incubation, was also rapid, reaching
intracellular concentrations lower than those obtained in pha-
gocytic cells but higher than extracellular concentrations (C/E
ratios 6.7 ± 1.1 and 10.8 ± 0.6, respectively).
HMR 3647 efflux
The elution of HMR 3647 from human PMOs was slow
(Figure 1). After 60 and 120 min of incubation ofloaded cells
in antimicrobial-free medium, the cell-associated antimicrobial
levels were 66% and 36%, respectively (compare 100% values at
20 min). Furthermore, after 24 h of incubation, cell-associated
HMR 3647 was about 25%. The elution from PMNs was
slower than that from PMOs. After 160 min of incubation in
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antimicrobial-free medium, the percentage ofketolide released
was ouly 40% (60% cell-associated HMR 3647).
The efflux ofketolide from the different tissue-cultured cells
evaluated was more rapid than that from human phagocytes.
The ketolide efflux from fibroblasts was similar to that obtained
from McCoy cells (data not shown). After 60 min ofincubation
in antimicrobial-free medium, the cell-associated HMR 3647
was 10% for McCoy cells and 31% for Hep-2 cells. All the
tissue-cultured cells lost almost 70% of cell-associated HMR
3647 after 1 h of incubation in an antimicrobial-free medium
(Figure 2).
Effect ofextracellular concentration on HMR 3647 uptake
The intracellular penetration of HMR 3647 into all types of
evaluated cells was not saturable at extracellular concentrations
ranging from 2 to 25 mg/L. At extracellular concentrations
ranging from 2 to 25 mg/L, the C/E ratios ranged from 61 to
78 for PMOs and from 57 to 66 for PMNs, respectively. With
the same extracellular concentration assay with tissue-cultured
cells, the C/E ratios ranged from 6.7 to 22.7 for McCoy, from
10.6 to 12.8 for Hep-2, and from 4.4 to 10.2 for fibroblast cells,
respectively.
Intracellular activity ofHMR 3647
The intracellular activity of HMR 3647 against Staphylococcus
aureusATCC 25923 was evaluated by 3-h assay. At extracellular
concentrations of 0.5, 1, 5 and 10 mg/L, HMR 3647 did not
Figure 1 Uptake and efflux (dotted line) of HMR 3647 in human PMNs and PMOs after removal of the extracellular drug (n = 4). Extracellular ketolide con-
centration: 2 mgjL.
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Figure 2 Uptake and efflux (dotted line) of HMR 3647 in McCoy and Hep-2 after removal of the extracellular drug (n = 4). Extracellular ketolide concentra-
tion: 2 mgjL.
significantly reduce the intracellular survival rate of Staphylo-
coccus aureus in PMNs (data not shown).
DISCUSSION
The intracellular activity ofan antimicrobial agent in phagocytic
cells is particularly important when the infecting microorgan-
isms are able to survive and multiply within cells. Previous
studies of the intracellular penetration ofHMR 3647 have used
human PMNs [9,13], but less information is available on the
intracellular pharmacology of these compounds in human
macrophages and non-phagocytic cells.
In this study, we observed that HMR 3647 reached intra-
cellular concentrations several times higher than extracellular
concentrations in both types of phagocytic cell (PMNs and
PMOs), tissue-cultured epithelial cells and fibroblasts. HMR
3647 was strongly accumulated by human PMNs and macro-
phages. The C/E maxima were 130.1 ± 12.2 and 71 ± 3 for
PMNs and PMOs, respectively. These values were higher than
those observed for dirithromycin, C/E 62 ± 21.2, and ery-
thromycin, C/E 23 ± 1.8, inPMNs [14], andlowerthan those
observedforazithromycin, C/E 393 ± 37.4, and HMR 3004,
C/E 461 ± 14.8 [15]. The C/Eratiovalues ofHMR3647 for
epithelial cells and fibroblasts were lower than those obtained
with PMNs and PMOs, but still greater than 6.
The uptake of HMR by both phagocytic and non-
phagocytic cells was rapid and non-saturable. To evaluate the
reversibility ofbinding ofHMR 3647 to human phagocytic and
tissue-cultured cells, we evaluated the kinetics of efflux. The
efflux ofantibiotics from human phagocytic and tissue-cultured
cells, was slow.The efflux of HMR 3647 from human PMNs
and PMOs suggests, as has been described for azithromycin
[16], that these cells could serve as a vehicle to transport
antibiotics and deliver them to sites of infection.
The intraphagocytic antimicrobial activity of HMR 3647
was lower than that expected from the concentrations obtained.
Intracellular activity of HMR against Staphylococcus aureus,
which is sometimes resistant to the normal phagolysosomal
environment, seems to be very limited. A possible explanation
for the low intracellular activity could be the limitation of the
method or the inhibition of the drug by intracellular pH [17].
The time-kill kinetics data demonstrated that HMR 3647
exhibits concentration- and inoculum-dependent bacteriostatic
activity against Staphylococcus aureus. Slow, time-dependent,
bactericidal activity was found at higher concentrations at
24 h [18]. In our experience of working with phagocytic cells
and Staphylococcus aureus, it is very difficult to ensure that after
3 h of incubation, viable staphyloccoci stay within the PMNs,
not outside: we could be measuring extracellular rather than
intracellular activity. Other authors have found HMR 3647 to
be effective in reducing growth in PMNs at 24 h and at
4 X MIC for Streptococcus pneumoniae [19]. These results do
not support the hypothesis of intracellular inactivation of the
drug by the pH and may be related to the bacteriostatic, not
bactericidal, effect of HMR 3647 against Staphylococcus aureus.
In summary, HMR 3647 penetrates human phagocytes and
tissue-cultured cells, reaching intracellular concentrations sev-
eral times higher than extracellular concentrations, but no
© 2001 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, GMI, 7, 65-69
improvement is obtained by reducing the intracellular survival
rate of Staphylococcus aureus in PMNs at 3 h.
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